Skip to main content
AVTX
NASDAQ Life Sciences

Avalo Therapeutics Reports 2025 Financials, Extends Cash Runway into 2028, and Anticipates Key Phase 2 Data in Q2 2026

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$13.4
Mkt Cap
$248.441M
52W Low
$3.39
52W High
$20.72
52W Position info
295% above low
Off High info
35% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

AVTX has more than doubled off its 52-week low of $3.39.

Summary

Avalo Therapeutics reported its 2025 financial results, including an increased net loss, but also announced an extended cash runway into 2028 and confirmed upcoming Phase 2 trial data in Q2 2026.


Key Events · Financing and Capital Events · AVTX

  • 2025 Financial Results Announced

    Avalo Therapeutics reported a net loss of $78.3 million for the year ended December 31, 2025, compared to a net loss of $35.1 million in 2024. Research and development expenses increased to $50.1 million, primarily driven by costs associated with the Phase 2 LOTUS trial.

  • Cash Runway Extended into 2028

    The company reported cash, cash equivalents, and short-term investments of $98.3 million as of December 31, 2025. This capital is expected to fund operations into 2028, providing significant financial stability.

  • Key Phase 2 Data Expected in Q2 2026

    Topline data from the Phase 2 LOTUS trial of abdakibart (AVTX-009) for hidradenitis suppurativa is anticipated in the second quarter of 2026, representing a major clinical milestone for the company.


Analysis · AVTX · Life Sciences

Avalo Therapeutics' 2025 financial results highlight an increased net loss, primarily due to higher R&D expenses for its Phase 2 LOTUS trial and non-recurring warrant-related expenses from 2024. However, the significant extension of its cash runway into 2028 provides crucial financial stability for a clinical-stage biotechnology company, alleviating near-term financing concerns. The upcoming topline data from the Phase 2 LOTUS trial in Q2 2026 represents a major catalyst, with potential to significantly impact the company's valuation and future prospects.

How filings like this one have moved

In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AVTX was trading at $13.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $248.4M. The 52-week trading range was $3.39 to $20.72. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AVTX - Latest Insights

AVTX
Nov 05, 2026, 7:58 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $6.91
Real-time Price: $7.15 info
Change: +$0.240 (+3%) info
Market Cap: $414.013M info
AVTX
Nov 05, 2026, 7:04 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $7.13
Real-time Price: $7.15 info
Change: +$0.020 (+0.28%) info
Market Cap: $414.013M info
AVTX
Aug 06, 2026, 7:03 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.69
Real-time Price: $7.15 info
Change: -$11.54 (-62%) info
Market Cap: $414.013M info
AVTX
Aug 06, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $18.69
Real-time Price: $7.15 info
Change: -$11.54 (-62%) info
Market Cap: $414.013M info
AVTX
Jun 23, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $15.04
Real-time Price: $7.15 info
Change: -$7.89 (-52%) info
Market Cap: $414.013M info